Hepatoma Research: Annual Report of 2018

Published on: 28 Jan 2019 Viewed: 180

On January 15, 2019, the Annual Report meeting of the Hepatoma Research was held in Xi’an, China. The report on the development of the journal over the past year was given by HR Editorial Office, which reads as follows.

Apparently, the biggest change of our journal is the launch of its newly designed website on December 4, 2018 which is the third overall upgrading since 2015. The new website has won a lot of praises from our readers, and they also pay much attention to the high-quality articles published in our journal in the year of 2018.

HR published 75 articles mainly from China, USA, Italy and Japan in 2018. Among them, 56 articles were from the special issues: 16 papers from “Molecular Mechanism of Hepatocellular Carcinoma”, organized by Prof. Seung Kew Yoon from Korea, 12 papers from “What More We can do on Hepatitis C?”, organized by Prof. Necati Örmeci from Turkey, 19 papers from “Management of Hepatocellular Carcinoma”, organized by Prof. Osamu Yokosuka from Japan, 9 papers from “New Insights in Liver Cancer”, organized by Prof. Clara Balsano from Italy. The most obvious improvement is that the number of articles has nearly doubled compared with 38 published articles in 2017. The quality of articles in 2018 has greatly improved thanks to the established of more special issues and a more scientific, rigorous peer-review process. The distribution of the authors’ countries in 2018 is shown as below:

Up to December 31, 2018, all papers have been read 890,516 times and downloaded 33,624 times. It has been read 73,177 times and downloaded 4,959 times in 2018. Compared with 2017, the reading volume increased by 27,948 and the download volume increased by 912. The maximum reading time for a single article is 3768 times, and the maximum download time for a single article is 246 times. Regarding the citation, all published articles were cited 77 times in 2018 (Searched by Web of Science). Top cited articles and top downloaded articles in recent 2 years could be found below:

TitleTypeCountryPublished Year
Further understanding of mechanisms involved in liver cancer chemoresistanceReviewSpain2017
Immunotherapy for hepatocellular carcinoma: the force awakens in HCC?ReviewUSA2017
Management of advanced hepatocellular carcinoma: review of current and potential therapiesReviewEgypt2017
Detection of urine DNA markers for monitoring recurrent hepatocellular carcinomaOriginal ArticleUSA2017
Antioxidant activity and free radical-scavenging of cape gooseberry (Physalis peruviana L.) in hepatocellular carcinoma rats modelOriginal ArticleEgypt2017
Later recurrence of hepatocellular carcinoma after liver transplantationOriginal ArticleUSA2017
Role of early growth response 1 in liver metabolism and liver cancerReviewUSA2017
Comparison of p53 and prohibitin expression in the spectrum of hepatitis, cirrhosis, and hepatocellular carcinomaOriginal ArticleBrazil2017
Reducing liver cancer risk beginning at birth: experiences of preventing chronic hepatitis B virus infection in ChinaReviewChina2017
Hepatocellular carcinoma following direct anti-viral for hepatitis C treatment: a report of an Egyptian case seriesCase ReportEgypt2017
MELD score and AST-to-platelet ratio index (APRI) predict long-term survival in patients with a small hepatocellular carcinoma following non-transplant therapies: a pilot studyOriginal ArticleUSA2017
Qidong hepatitis B virus infection cohort: a 25-year prospective study in high risk area of primary liver cancerCohort fileChina2018
Lycopene treatment stalls the onset of experimentally induced hepatocellular carcinoma: a radioisotopic, physiological and biochemical analysisOriginal ArticleIndia2018
Mitoepigenetics and hepatocellular carcinomaReviewMexico2018
HCV clearance by direct antiviral therapy and occurrence/recurrence of hepatocellular carcinoma: still an issue?ReviewItaly2018
The multifaceted oncogene SND1 in cancer: focus on hepatocellular carcinomaReviewUSA2018
Fat and hepatocellular carcinomaReviewItaly2018
Elimination of hepatitis from Pakistan by 2030: is it possible?OpinionPakistan2018

(Top Cited papers in 2017 and 2018)

(Top downloaded papers in 2018 and 2017)

The progress of journals has been recognized by more professionals. Nine new Editorial Board Members from USA, Japan, Italy, China, and Turkey have joined our journal in 2018: Prof. Osamu Yokosuka (Chiba University, Japan, Former President of APASL), Prof. Seung Kew Yoon (The Catholic University of Korea, Korea), Prof. Clara Balsano (University of L'Aquila, Italy), Prof. Necati Örmeci (Ankara University Medical School, Turkey, Executive Council of APASL), Prof. Bruno Nardo (Alma Mater Studiorum Università di Bologna), Prof. Gabriele Missale (Azienda Ospedaliero-Universitaria di Parma), and other experts from University of Iowa, USA and China, etc.

The readership of HR expanded from 168 countries and regions in 2017 to 186 in 2018. The detailed distribution can be seen in the following chart:

Furthermore, the Third Editorial Board Meeting of HR was held in Xi’an on September 22rd. There were 18 editorial board members with top academic backgrounds attending the meeting, including: Prof. Guang-Wen Cao (Naval Medical University), Editor-in-Chief; Prof. Masao Omata (University of Tokyo), Honorary Editor-in-Chief; Prof. Kai-Chun Wu (Fourth Military Medical University), Associate Editor; Prof. Osamu Yokosuka (Chiba University), Associate Editor; Prof. Kenneth Siu Ho Chok (University of Hong Kong), Associate Editor, etc. Prof. Cao held a discussion on the journal development and hot topics in liver cancer. The progress made in the past year has been highly praised by Prof. Masao Omata, who expressed his confidence in the promising future of HR.

In 2018, we succeeded in carrying out the plan made at the beginning of the year and achieved gratifying achievements recognized by experts in the field of liver cancer research. We’d like to express our sincere gratitude to the experts for their contributions to peer review in the past 3 years on behalf of the editorial team. (Please kindly find from Reviewer Acknowledgments for detailed information)

We firmly believe that the journal will achieve more remarkable development in 2019 with the joint efforts by all members of HR.

Respectfully Submitted by the Editorial Office of Hepatoma Research.